The Fibromyalgia Survey Diagnostic Criteria-2016 (FSD-2016 criteria) were recently recommended for both clinical and research purposes. The present study aims to examine whether there is concordance between clinician-based and FSD-2016 criteria-based diagnoses of FM, and secondly, to examine how the illness severity and physical function relate to the criteria-based diagnosis among patients referred to a rheumatism hospital.
Participants with a clinician-based diagnosis of FM were included consecutively when referred to a patient education programme for patients with FM. Illness severity was assessed with the Fibromyalgia Survey Questionnaire (FSQ). Based on the FSQ, the fulfilment of the FSD-2016 criteria was evaluated. Physical function was assessed using the Fibromyalgia Impact Questionnaire (FIQ) function scale and self-reported employment status.
The sample included 130 patients (84% women) from 20 to 66 years of age. Eighty-nine per cent met the FSD-2016 criteria, and 44% of the patients were fully or partially employed. Great variability in illness severity was seen irrespective of employment status. There was an association between illness severity and physical function (r=0.4, p<0.001). For 95% of the patients, the FSQ illness severity scores classify as severe or very severe, and even for those not fulfilling the diagnostic criteria the scores were moderate and severe.
There was relatively high agreement between clinician- and criteria-based diagnoses. The illness severity overlapped irrespective of different employment status and fulfilment of FSD-2016 criteria.
Fibromyalgia (FM) is a contested widespread musculoskeletal pain condition that cannot be confirmed by laboratory or radiological assessments. Patients experience persistent pain with an unpredictable fluctuating intensity , and they report multiple other problems, e.g. pronounced fatigue, sleep and concentration problems, depression, headache, irritable bowel, and impaired functioning . FM is explained by multiple interacting mechanisms such as hypersensitivity of the central nervous system, deficits in endogeneous pain inhibition, alterations in the neuroendocrine system, autonomic nervous system, immune system and stress regulation mechanisms, and additionally, by genetic vulnerability and psychological mechanisms , , . There is no known curative treatment for FM, but the European League Against Rheumatism highlights the importance of an early diagnosis in order to start treatment tailored to the individual’s needs and illness severity .
A challenge in the diagnostic process is that the symptoms of FM mimic a number of other diseases such as within rheumatology, neurology and psychiatry . Accordingly, patients are often sent to various medical specialists for diagnostics , and it may take years to arrive at a FM diagnosis . Meanwhile, patients may worry and fear the worst, and additionally, health professionals and others may accuse patients of exaggerating bodily sensations . For patients, it can be a relief to get a diagnosis confirming not having a progressive or fatal disease , and patients may find it better to have a FM diagnosis than having no diagnosis .
Since the 1970s, several diagnostic criteria sets have been published . Until recently, the most influential has been the American College of Rheumatology criteria from 1990 (ACR-1990 criteria) . According to these criteria, pain should have persisted for at least three months, generalized by being present axially, and above and below the waistline on the right and left sides. Additionally, at least 11 of 18 defined points should generate pronounced tenderness from thumb palpation pressure of 4 kg/cm2. The ACR-1990 criteria have been applied for research purposes worldwide. However, physicians in clinical practice, particularly non-rheumatologists, have often either ignored the criteria or performed the tender point examination incorrectly . Thus, in the 2000s, new diagnostic criteria have been developed that eliminate the tender point assessment in order to make criteria reliable and applicable for both clinical and research purposes, and thereby, ensure that research generates clinical relevant knowledge.
Like in the ACR-1990 criteria, the preliminary ACR-2010 criteria required that pain should have persisted for at least three months. The ACR-2010 criteria replaced the requirements of generalized pain and tender point count with an illness severity scale, the Fibromyalgia Survey Questionnaire (FSQ), based on the number of pain sites and the severity of other symptoms related to FM . In 2011, the ACR-2010 criteria were revised to the modified 2010/2011-criteria so that they could be applicable as self-reports in epidemiological studies . However, the authors later demonstrated that in a rheumatology clinic, clinician-based diagnoses failed to identify about 50% of those fulfilling the modified 2010/2011 criteria-based diagnosis . In 2016, a new revision was launched, the Fibromyalgia Survey Diagnostic-2016 criteria (FSD-2016 criteria). Here, the criterion of generalized pain was added to the modified 2010/2011 criteria defined as the presence of pain in at least four of the five body regions defined earlier in the ACR-1990-criteria, and additionally, the FSD-2016 criteria do not rule out concomitant diagnoses . Whereas the ACR-1990 criteria emphasised allodynia, the FSD-2016 criteria seems to focus more on central pain perceptions and distress .
In 2019, another criteria set was launched by the American Pain Association , the AAPT-2019 criteria. In addition to pain, the occurrence of moderate to severe degree of fatigue or sleep problems is required, and generalized pain is defined as at least six out of nine defined pain sites. The AAPT-2019 criteria lack an illness severity scale, it is dichotomous in fulfilling a FM diagnosis or not and have not been translated or validated in a Norwegian setting. However, the FSD-2016 criteria and the FSQ were recently translated and found valid in a Norwegian context . Still, it remains to examine whether these criteria match clinicians’ judgement of diagnosis. Our purpose was to examine whether there is concordance between the FM diagnosis determined by the FSD-2016 criteria and clinicians’ judgements of FM diagnosis, and secondly, to examine how illness severity and physical functioning relates to the criteria-based diagnosis.
Patients and methods
Design and ethics
A cross-sectional study design was applied. Participants were included in the study during a six-month period in 2018. They were recruited consecutively as they were referred by physicians to a patient education programme for patients with FM at the Rehabilitation Department at the Hospital for Rheumatic Diseases in Lillehammer, Norway. Most of the patients were referred by physicians in primary health care while about one third were referred by medical specialists at the outpatient hospital clinic. The Norwegian Social Science Data Service approved the study (no. 2018/57956/3/EPA). The study complies with the Helsinki Declaration. The patients received written and oral information about the purpose and content of the study and the voluntary nature of participation. All patients accepted the invitation and signed a consent form.
The patients filled in a structured questionnaire about personal characteristics in terms of age, gender, education, and occupational status, as well as information about illness duration, whether and when a FM diagnosis was set, and their use of health services in relation to FM.
The Fibromyalgia Survey Questionnaire (FSQ) was used to assess illness severity . The Norwegian version of the FSQ which was recently found valid and reliable , was used. The patients indicated whether they perceived any pain in 19 different body sites. The number of pain localisations/sites was summarised in the Widespread Pain Index (WPI) with a possible range from 0 (best) to 19 (worst). The Symptom Severity Score (SSS) expresses the sum of impacts from exhaustion, cognitive problems, and waking up without feeling refreshed evaluated on a 4-graded scale (0=no problem, 3=great impact), and adds the number of occurrence of the following symptoms; pain/spasm in the lower abdomen, depression, or headache during the last six months. The SSS can range from 0 (best) to 12 (worst). The sum of WPI and SSS provides the FSQ total score (FS-score), which expresses the illness severity (scores 0=best, 31=worst). Based on the FS-score, the illness severity is graded into none (0–3), mild (4–7), moderate (8–11), severe (12–19), or very severe (20–31) .
Evaluation of criteria-based diagnosis
The Fibromyalgia Survey Diagnostic Criteria – 2016 (FSD-2016 criteria) are evaluated based on the FSQ. To fulfil the fibromyalgia criteria, the pain must have lasted for at least three months, WPI≥7 and SSS≥5, alternatively WPI from 4–6 and SSS≥9, and additionally, pain must be localised in at least four of five body regions: axial, right/left upper and lower limbs .
Problems in performing daily activities
The Fibromyalgia Impact Questionnaire (FIQ) function scale assesses problems in performing everyday life activities . In this study, we applied the FIQ function scale including questions about the ability to perform 10 different daily life activities (0=never, 3=always). The scores were summed, divided by the number of answered items, and multiplied by 3.33, which gives a score from 0 (best) to 10 (worst). The FIQ function scale has demonstrated moderate to good validity and reliability .
SPSS version 26 was used for data analyses. Ordinal data are provided in numbers and percentages, and continuous data as averages and standard deviations (SD). Both parametric and non-parametric tests were applied to analyse the correlations between variables and group differences. p-Values for two-sided hypotheses at 5% were considered statistically significant.
Patient characteristics and use of health services
All invited patients agreed to participate (n=130). Table 1 displays patients’ characteristics and use of health services. Of the patients, 84% were women, and 44% were fully or partially employed. Fifty-nine per cent of the participants were diagnosed within the last year. In the total sample, the time since diagnosis ranged from 1 month to 33 years. The patients had been examined by several medical specialists, undergone various specialised radiological assessments, and the patients had been treated by multiple health professionals.
|Mean (standard deviation)||Minimum – maximum||Numbers||Per cent of n=130|
|Age, in years||45 (11)||20–66|
|Symptom duration, in years||11 (11)||0.6–42|
|Time since diagnosis, in years||4.4 (8)||0.1–33|
|Consulted medical specialists|
*Most frequent reported comorbidities: osteoarthritis (n=15), degenerative low back/neck (n=4), chronic fatigue syndrome (n=3), hypermobility syndrome (n=3).
Clinically set diagnosis and concordance to criteria-based diagnosis
One hundred and 24 patients (95%) out of 130 reported having a clinician-set FM diagnosis, and six patients reported being under diagnostic investigation. All patients in the sample reported duration of pain for more than three months, and all but one had axial pain. One hundred and 16 patients (89%), including the six patients under diagnostic investigation, met the FSD-2016 criteria. Of the 14 patients who did not fulfil the criteria, 10 reported pain in only three body regions, while another four did not reach the criteria for WPI and/or SSI. However, comparing the clinician-based diagnosis with the modified 2010/2011 criteria which do not include the definition claimed for generalized pain, 96% of the total sample met these criteria. Of those not fulfilling the FSD-2016 criteria (among those five men, three partly/fully employed), nine patients were diagnosed during the last year and five more than 15 years ago.
Fibromyalgia severity and functional ability in relation to criteria-based diagnosis
Table 2 shows the FSQ scores and the FIQ physical function for the total sample. The FSQ total (FS-score) varied from mild to very severe; whereas according to the classification of illness severity, 1% of the patients had mild, 4% moderate, 23% severe, and 72% very severe. There was no difference between illness severity (FS-score) and FIQ physical function for those working full-time/part-time and those not working (full sickness/disability benefit, unemployed), p>0.05. A detailed description of the illness severity measured by the FS-score showed a large overlap between patients with different employment status (Figure 1). Figure 2 shows the distribution in the FS-score and the FIQ function score in relationship to fulfilment of diagnostic criteria. For the whole sample, a statistically significant correlation was found between the FS-score and the FIQ function score (r=0.4, p<0.001). Those who did not meet the FSD-2016 criteria had lower illness severity than those meeting the criteria, 13.6 (1.5) vs. 23.0 (3.8), p<0.001 and better physical functioning 3.6 (1.5) vs. 4.9 (2.3), p=0.04 than the others, as illustrated in Figure 2, but still they had moderate or severe FM.
|Patients, n=130||Mean (standard deviation)||Minimum – maximum scores|
|Fibromyalgia Survey Questionnairea|
|Fibromyalgia Impact Questionnairea|
aZero is the best scores.
Eighty-nine per cent of the patients who were diagnosed clinically or were under clinical diagnostic evaluation for FM fulfilled the FSD-2016 criteria. In the whole sample, patients had consulted several medical specialists and tried out therapies provided by various health professionals. There was a large overlap in illness severity between groups of different employment status.
Presently, the concordance between the criteria- and clinician-based diagnoses was rather good. Multiple physicians had set the clinical diagnosis of FM, and we do not know how they had arrived at their decisions. It is likely that the diagnostic process and judgements among the numerous primary health physicians and among the medical specialists at the hospital varied substantially. Nevertheless, their clinical diagnosis accorded to a great degree with the criteria-based diagnosis. One explanation can be that the FSD-2016 criteria capture a shared opinion among Norwegian physicians that multi-sited pain together with multiple other symptoms are hallmarks of FM. It is unlikely, however, that many of the clinicians applied the Norwegian version of the FSD-2016 criteria as they were not yet implemented. Furthermore, the recruitment of participants to the Norwegian criteria validation study  and our study were performed at the same time in two different geographical regions in Norway. Thus, we think that the clinician-based diagnosis largely reflects clinical experiential judgement with or without support from the ACR-1990 or the modified 2010/2011 criteria.
Another Norwegian study examined the fulfilment of the FSD-2016 criteria among 33 Norwegian patients referred to a specialised pain clinic. They were included if they had experienced pain for at least three months and met the requirement of generalized pain in at least four out of five body regions . Among those selected patients, 82% also fulfilled the illness severity required by the FSD-2016 criteria. In contrast to this study, we included all those previously diagnosed by clinicians and referred to a FM treatment programme. Even though both studies found high fulfilment of the FSD-2016 criteria, our inclusion criteria differed whereas Tschudi-Madsen et al.  included their patients when they fulfilled the generalized pain of the FSD-2016 criteria, whereas we included patients previously been diagnosed clinically. Salaffi and coworkers  examined 732 Italian patients referred by primary health physicians to diagnostic evaluation in a rheumatology clinic based on history of chronic widespread pain. The rheumatologists found that 405 patients had FM. The rheumatologists’ clinical-based diagnosis was set as a criterion for analysis, and sensitivity and specificity were found to be high for the modified 2010/2011 criteria, somewhat less so for the FSD-2016 criteria, and poorest for the AAPT-2019 criteria. In addition, our results showed an even better agreement between clinician- and criteria-based diagnoses if we excluded the criterion of generalized pain. Ten patients fulfilled the criteria of multisite pain (WPI score), but did not fulfil the FSD-2016 criteria as they had only spatially distributed pain in three out of at least four required spatial regions. For their part, Wolfe et al.  identified 121 patients meeting the modified 2010/2011 criteria among a sample of 497 patients in a university rheumatology clinic, and there was 79% agreement between clinician- and criteria-based diagnoses. However, the rheumatologists also failed to identify 49.6% of criteria-positive patients and incorrectly included 11.4% of criteria-negative patients. Looking across these studies, the concordance between clinician- and criteria-based diagnoses was rather high in all studies, but somewhat higher in our study than in the other studies. It is plausible, however, that the high agreement between clinician- and criteria-based diagnosis in our study was that our patients were not sent to a diagnostic evaluation, but to participate in a multidisciplinary patient education programme. The relatively high degree of measured illness severity suggests that the diagnosis may have been unmistakable for the clinicians and that it might have been different if patients were less severely afflicted. Promising though is that general practitioners and not specialists in rheumatology mostly had set the diagnosis, and therefore indicate that the criteria is applicable for non-rheumatologists. Taken together, the studies suggest that the use of FSD-2016 criteria for research purposes include patients evaluated by physicians to have FM. However, our study can neither approve nor refute the suggestion of Arnold and Clauw  that many patients may be underdiagnosed and undertreated. The high number of earlier treatments for FM with little success in our study, however, suggests that patients are not undertreated, but rather inadequately treated. Accordingly, we agree with Clauw’s  statement that we have to stop the ‘FM diagnostic criteria war’ and find out how to better treat the patients.
Previously, an almost linear association between the number of pain sites and the occurrence of a number of non-musculoskeletal symptoms has been demonstrated . In our study, the illness severity assessed by the FSQ of most patients were classified as severe and very severe, and none of the patients were in the range of no severity. Even those not fulfilling the FSD-2016 criteria had FS-scores classified as either moderate or severe. However, most of the symptoms evaluated by the FSQ are not exclusive to FM, for example, the symptoms are rather common in many chronic non-malignant pain conditions. In our sample most of those not meeting the FSD-2016, had multiple painful sites but only in three of the least required four body regions. If there are multi-sited pain in three instead of four bodily regions together with moderate or severe FS-scores, we suggest that clinicians should consider the possibility that their patient might benefit from treatments given to patients with FM [28, 29].
In line with the findings of Choy et al. , the patients in the present study had also consulted several medical specialists and many had undergone several advanced radiological assessments. It may be necessary to perform such assessments for the purpose of differential diagnosis or for identifying comorbidities, but it often takes time. In their survey, Choy et al.  found that a diagnostic journey took years. Unfortunately, we have no data about the time it took before a decision about diagnosis was taken. However, the reported use of health services in our study demonstrates another challenge, namely that both before and after diagnosis, patients are sent to several health professionals in order to try out different treatments. This is in line with the findings of a meta-synthesis that first described a time-consuming diagnostic journey which, after being diagnosed, was replaced by another long journey to find appropriate help . Thus, it seems important to identify patients earlier and develop better ways to help individual patients. Patients do not necessarily experience less uncertainty when their symptoms are classified and named , and without appropriate explanations and treatments, the doctor-patient interactions can be challenged [31, 32].
It is a strength of the study that we succeeded in recruiting all the patients referred to a patient education programme for patients with FM. However, the sample size is not very large, the study was conducted at only one hospital, and most of the patients had very severe illness. The patients were referred by multiple physicians from a wide geographic region, though. The clinicians’ judgements and referral practices are essential in the present study. It is thus a shortcoming that we do not know anything about the physicians who set the diagnosis and how they arrived at it. On the other hand, it is a strength that the physicians were not aware that we would check their clinical diagnoses against diagnostic criteria. Accordingly, the clinician-based diagnoses reflect a ‘real-life’ situation, and it is in this study a strength to include many different physicians. Nevertheless, the high agreement between clinician- and criteria-based diagnoses cannot be generalised to all patients diagnosed by physicians, as 72% in our sample had very severe illness. Thus, future studies should also examine the agreement if patients have less severe illness. Nevertheless, it is likely that using the FSD-2016 criteria for research purposes will provide important knowledge for clinical use concerning those most afflicted in clinical practice.
The findings of our study showed relatively good concordance between clinician- and criteria-based diagnoses of FM among patients mostly classified with very severe illness. Those not fulfilling the FM criteria also had moderate or severe illness scores. The illness severity varied and overlapped in groups with different employment status. The patients had often consulted several medical specialists and been treated by therapists with various professional backgrounds.
Funding source: DAM Foundation
Award Identifier / Grant number: 2018/57956/3/EPA
Thanks to employees at the Rehabilitation Department at the Rheumatic Disease Hospital, Lillehammer, Norway, who participated in the data collection.
Research funding: The DAM Foundation through the Norwegian Women Association [no. 2017/HE2-184218] funded the study, neither of which have any commercial interests.
Author contributions: The authors fulfil the ICMJE criteria for authorship.
Competing interests: All authors state that there are no conflicts of interest.
Informed consent: All participants signed an informed consent before inclusion.
Ethical approval: The Norwegian Social Science Data Service approved the study (no. 2018/57956/3/EPA) and the study was performed in accord with the Helsinki Declaration.
1. Sim, J, Madden, S. Illness experience in fibromyalgia syndrome: a metasynthesis of qualitative studies. Soc Sci Med 2008;67:57–67. https://doi.org/10.1016/j.socscimed.2008.03.003.Search in Google Scholar PubMed
2. Arnold, LM, Crofford, LJ, Mease, PJ, Burgess, SM, Palmer, SC, Abetz, L, et al.. Patient perspectives on the impact of fibromyalgia. Patient Educ Counsel 2008;73:114–20. https://doi.org/10.1016/j.pec.2008.06.005.Search in Google Scholar PubMed PubMed Central
3. Littlejohn, G, Guymer, E. Key milestones contributing to the understanding of the mechanisms underlying fibromyalgia. Biomedicines 2020;8:223. https://doi.org/10.3390/biomedicines8070223.Search in Google Scholar PubMed PubMed Central
4. Arnold, LM, Bennett, RM, Crofford, LJ, Dean, LE, Clauw, DJ, Goldenberg, DL, et al.. AAPT diagnostic criteria for fibromyalgia. J Pain 2019;20:611–28. https://doi.org/10.1016/j.jpain.2018.10.008.Search in Google Scholar PubMed
5. Rahman, MS, Winsvold, BS, Chavez-Chavez, SO, Børte, S, Tsepilov, YA, Sharapov, SZ, et al.. Genome-wide association study identifies RNF123 locus as associated with chronic widespread musculoskeletal pain. Ann Rheum Dis 2021 Sep 1. https://doi.org/10.1136/annrheumdis-2020-219624 [Epub ahead of print].Search in Google Scholar PubMed PubMed Central
6. Macfarlane, GJ, Kronisch, C, Dean, LE, Atzeni, F, Hauser, W, Fluss, E, et al.. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017;76:318–28. https://doi.org/10.1136/annrheumdis-2016-209724.Search in Google Scholar PubMed
7. Choy, E, Perrot, S, Leon, T, Kaplan, J, Petersel, D, Ginovker, A, et al.. A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv Res 2010;10:102. https://doi.org/10.1186/1472-6963-10-102.Search in Google Scholar PubMed PubMed Central
8. Mengshoel, AM, Sim, J, Ahlsen, B, Madden, S. Diagnostic experiences of patients with fibromyalgia – a meta-ethnography. Chron Illness 2018;14:194–211. https://doi.org/10.1177/1742395317718035.Search in Google Scholar PubMed
9. White, KP, Nielson, WR, Harth, M, Ostbye, T, Speechley, M. Does the label “fibromyalgia” alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Care Res 2002;47:260–5. https://doi.org/10.1002/art.10400.Search in Google Scholar PubMed
10. Wang, S-M, Han, C, Lee, S-J, Patkar, AA, Masand, PS, Pae, C-U. Fibromyalgia diagnosis: a review of the past, present and future. Expert Rev Neurother 2015;15:667–79. https://doi.org/10.1586/14737175.2015.1046841.Search in Google Scholar PubMed
11. Wolfe, F, Smythe, HA, Yunus, MB, Bennett, RM, Bombardier, C, Goldenberg, DL, et al.. The American College of Rheumatology 1990: criteria for the classification of fibromyalgia. Report of the Mulicenter Criteria Committee. Arthritis Rheum 1990;33:160–72. https://doi.org/10.1002/art.1780330203.Search in Google Scholar PubMed
13. Wolfe, F, Clauw, DJ, Fitzcharles, M-A, Goldenberg, DL, Katz, RS, Mease, P, et al.. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62:600–10. https://doi.org/10.1002/acr.20140.Search in Google Scholar PubMed
14. Wolfe, F, Clauw, DJ, Fitzcharles, MA, Goldenberg, DL, Häuser, W, Katz, RS, et al.. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 2011;38:1113–22. https://doi.org/10.3899/jrheum.100594.Search in Google Scholar PubMed
15. Wolfe, F, Schmukler, J, Jamal, S, Castrejon, I, Gibson, KA, Srinivasan, S, et al.. Diagnosis of fibromyalgia: disagreement between fibromyalgia criteria and clinician-based fibromyalgia diagnosis in a university clinic. Arthritis Care Res 2019;71:343–51. https://doi.org/10.1002/acr.23731.Search in Google Scholar PubMed
16. Wolfe, FMD, Clauw, DJMD, Fitzcharles, M-AMD, Goldenberg, DLMD, Häuser, WMD, Katz, RLMD, et al.. 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46:319–29. https://doi.org/10.1016/j.semarthrit.2016.08.012.Search in Google Scholar PubMed
17. Galvez-Sánchez, CM, Reyes Del Paso, GA. Diagnostic criteria for fibromyalgia: critical review and future perspectives. J Clin Med 2020;9:1219. https://doi.org/10.3390/jcm9041219.Search in Google Scholar PubMed PubMed Central
18. Fors, EA, Wensaas, KA, Eide, H, Jaatun, EA, Clauw, DJ, Wolfe, F, et al.. Fibromyalgia 2016 criteria and assessments: comprehensive validation in a Norwegian population. Scand J Pain 2020;20:663–72. https://doi.org/10.1515/sjpain-2020-0002.Search in Google Scholar PubMed
19. Häuser, W, Jung, E, Erbslöh-Möller, B, Gesmann, M, Kühn-Becker, H, Petermann, F, et al.. Validation of the fibromyalgia survey questionnaire within a cross-sectional survey. PLoS One 2012;7:e37504-e. https://doi.org/10.1371/journal.pone.0037504.Search in Google Scholar PubMed PubMed Central
20. Wolfe, F, Walitt, BT, Rasker, JJ, Katz, RS, Häuser, W. The use of polysymptomatic distress categories in the evaluation of fibromyalgia (FM) and FM severity. J Rheumatol 2015;42:1494–501. https://doi.org/10.3899/jrheum.141519.Search in Google Scholar PubMed PubMed Central
21. Burchardt, CS, Clark, SR, Bennett, RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728–33.Search in Google Scholar
23. Tschudi-Madsen, H, Rødevand, LN, Bøymo Kaarbø, M, Granan, LP. Chronic widespread pain in a tertiary pain clinic: classification overlap and use of a patient generated quality of life instrument. Scand J Pain 2019;19:245–55. https://doi.org/10.1515/sjpain-2018-0097.Search in Google Scholar PubMed
24. Salaffi, F, Di Carlo, M, Farah, S, Atzeni, F, Buskila, D, Ablin, JN, et al.. Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified fibromyalgia assessment status. Rheumatology 2020;59:3042–9. https://doi.org/10.1093/rheumatology/keaa061.Search in Google Scholar PubMed
25. Arnold, LM, Clauw, DJ. Challenges of implementing fibromyalgia treatment guidelines in current clinical practice. Postgrad Med 2017;129:709–14. https://doi.org/10.1080/00325481.2017.1336417.Search in Google Scholar PubMed
26. Clauw, D. Time to stop the FM criteria wars – and refocus on identifying and treating individuals with this type of pain earlier in their illness. Arthritis Care Res 2020 Apr 5. https://doi.org/10.1002/acr.24198 [Epub ahead of print].Search in Google Scholar PubMed
27. Tschudi-Madsen, H, Kjeldsberg, M, Natvig, B, Ihlebaek, C, Dalen, I, Kamaleri, Y, et al.. A strong association between non-musculoskeletal symptoms and musculoskeletal pain symptoms: results from a population study. BMC Muscoskel Disord 2011;12:285. https://doi.org/10.1186/1471-2474-12-285.Search in Google Scholar PubMed PubMed Central
28. Landrø, NI, Fors, EA, Våpenstad, LL, Holthe, Ø, Stiles, TC, Borchgrevink, PC. The extent of neurocognitive dysfunction in a multidisciplinary pain centre population. Is there a relation between reported and tested neuropsychological functioning? Pain 2013;154:972–7. https://doi.org/10.1016/j.pain.2013.01.013.Search in Google Scholar PubMed
29. Kamaleri, Y, Natvig, B, Ihlebaek, CM, Bruusgaard, D. Localized or widespread musculoskeletal pain: does it matter? Pain 2008;138:41–6. https://doi.org/10.1016/j.pain.2007.11.002.Search in Google Scholar PubMed
30. Boulton, T. Nothing and everything: fibromyalgia as a diagnosis of exclusion and inclusion. Qual Health Res 2018;29:809–19. https://doi.org/10.1177/1049732318804509.Search in Google Scholar PubMed
31. Armentor, JL. Living with a contested, stigmatized illness: experiences of managing relationships among women with fibromyalgia. Qual Health Res 2017;27:462–73. https://doi.org/10.1177/1049732315620160.Search in Google Scholar PubMed
32. Colmenares-Roa, T, Huerta-Sil, G, Infante-Castaneda, C, Lino-Perez, L, Alvarez-Hernandez, E, Pelaez-Ballestas, I. Doctor – patient relationship between individuals with fibromyalgia and rheumatologists in public and private health care in Mexico. Qual Health Res 2016;26:1674–88. https://doi.org/10.1177/1049732315588742.Search in Google Scholar PubMed
© 2021 Anne Marit Mengshoel et al., published by De Gruyter, Berlin/Boston
This work is licensed under the Creative Commons Attribution 4.0 International License.